Exclusive: Pfizer leaning toward abandoning deal with Allergan - source
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Exclusive: Pfizer leaning toward abandoning deal with Allergan - source
April 6, 2016 10:42 AM EDT
BMO Capital reiterated an Outperform rating and $39.00 price target on Pfizer (NYSE: PFE) following the company's announcement the merger agreement with Allergan plc was terminated. BMO believes that Pfizer will likely look for more deals to strengthen its innovative business, and the recent weakness... More
April 6, 2016 7:13 AM EDT
Leerink Partners maintained an Outperform rating on Allergen (NYSE: AGN), and cut the price target to $272.00 (from $340.00), following new U.S. Treasury regulations. The Treasury's temporary regulation regarding new tax inversion rules creates a risk to PFE (MP) - AGN closing.
Analyst Jason Gerberry... More
April 5, 2016 3:47 PM EDT
BTIG issued brief commentary on Allergan (NYSE: AGN) following the U.S. Treasury's tax inversion actions on Monday night.
Analyst Timothy Chiang commented on potential routes for Allergan if its deal with Pfizer (NYSE: PFE)... More
April 5, 2016 3:45 PM EDT
Deutsche Bank analsyt Gregg Gilbert said his stand-alone price target for Allergen (NYSE: AGN) is $282. Comments follow reports its deal with Pfizer (NYSE: PFE) could be in jeopardy given the U.S. Treasury's changes targeting tax inversions.
"Recall that we have been using a deal-driven price target... More
